Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Abivax (ABVX) Shares Outstanding (Weighted Average) (2022 - 2025)

Historic Shares Outstanding (Weighted Average) for Abivax (ABVX) over the last 5 years, with Q3 2025 value amounting to $85.3 million.

  • Abivax's Shares Outstanding (Weighted Average) rose 2281.21% to $85.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $85.3 million, marking a year-over-year increase of 2281.21%. This contributed to the annual value of $67.4 million for FY2024, which is 4461.88% up from last year.
  • Per Abivax's latest filing, its Shares Outstanding (Weighted Average) stood at $85.3 million for Q3 2025, which was up 2281.21% from $1799.8 recorded in Q2 2025.
  • In the past 5 years, Abivax's Shares Outstanding (Weighted Average) registered a high of $85.3 million during Q3 2025, and its lowest value of $873.06 during Q1 2025.
  • In the last 5 years, Abivax's Shares Outstanding (Weighted Average) had a median value of $32.9 million in 2022 and averaged $37.4 million.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first surged by 13787.88% in 2023, then plummeted by 9999.87% in 2025.
  • Over the past 5 years, Abivax's Shares Outstanding (Weighted Average) (Quarter) stood at $17.7 million in 2021, then grew by 10.17% to $19.5 million in 2022, then soared by 137.88% to $46.3 million in 2023, then soared by 45.4% to $67.4 million in 2024, then grew by 26.58% to $85.3 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $85.3 million in Q3 2025, compared to $1799.8 in Q2 2025 and $873.06 in Q1 2025.